| Q92576211 | A pilot study of pembrolizumab in smoldering myeloma: report of the clinical, immune, and genomic analysis |
| Q39136762 | Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progression |
| Q55692949 | Anti-PD1 associated fulminant myocarditis after a single pembrolizumab dose: the role of occult pre-existing autoimmunity. |
| Q92812162 | Bone Marrow Stromal Cells-Induced Drug Resistance in Multiple Myeloma |
| Q39093915 | Bone marrow micro-environment is a crucial player for myelomagenesis and disease progression. |
| Q52679939 | Bone marrow-derived mesenchymal stem cells promote cell proliferation of multiple myeloma through inhibiting T-cell immune responses via PD-1/PD-L1 pathway. |
| Q57491415 | Checkpoint Inhibition in Myeloma: Opportunities and Challenges |
| Q38787767 | Checkpoint inhibition in myeloma. |
| Q33651495 | Checkpoint inhibitors in hematological malignancies |
| Q47348957 | Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update. |
| Q39102170 | Current treatment options of T cell-associated immunotherapy in multiple myeloma |
| Q92996778 | Daratumumab prevents programmed death ligand-1 expression on antigen-presenting cells in de novo multiple myeloma |
| Q47340203 | Emerging options in multiple myeloma: targeted, immune, and epigenetic therapies. |
| Q52668568 | Enumeration, functional responses and cytotoxic capacity of MAIT cells in newly diagnosed and relapsed multiple myeloma. |
| Q58691451 | Expression of PD-1 and PD-L1 increase in consecutive biopsies in patients with classical Hodgkin lymphoma |
| Q92867679 | Identification of key candidate genes and pathways in multiple myeloma by integrated bioinformatics analysis |
| Q94475277 | Identification of the immune checkpoint signature of multiple myeloma using mass cytometry-based single-cell analysis |
| Q64950921 | Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies. |
| Q64107945 | Immunogenic Cell Death and Immunotherapy of Multiple Myeloma |
| Q38692244 | Immunologic approaches for the treatment of multiple myeloma |
| Q48169937 | Immunopathogenesis and immunotherapy of multiple myeloma. |
| Q58123214 | Immunophenotyping of Orthotopic Homograft (Syngeneic) of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry |
| Q61813810 | Immunotherapy in myeloma: how far have we come? |
| Q38832525 | International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma |
| Q39084427 | Is immunotherapy here to stay in multiple myeloma? |
| Q99404848 | Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells |
| Q92350689 | Lessons Learned from Checkpoint Blockade Targeting PD-1 in Multiple Myeloma |
| Q38979865 | MGUS to myeloma: a mysterious gammopathy of underexplored significance |
| Q52630284 | Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway. |
| Q89565340 | Molecular basis of clonal evolution in multiple myeloma |
| Q64890377 | Multiple Myeloma: What Do We Do About Immunodeficiency? |
| Q38640444 | Novel Immunotherapies for Multiple Myeloma |
| Q57486479 | Novel Strategies for Peptide-Based Vaccines in Hematological Malignancies |
| Q47326177 | Oncolytic virotherapy as an immunotherapeutic strategy for multiple myeloma |
| Q41926342 | PD-1 and PD-L1 co-expression predicts favorable prognosis in gastric cancer |
| Q89776901 | PD-1 blockade enhances elotuzumab efficacy in mouse tumor models |
| Q39420466 | PD-1/PD-L1 inhibitors in haematological malignancies: update 2017. |
| Q38765760 | PD-1/PD-L1 inhibitors in multiple myeloma: The present and the future |
| Q98158713 | PD-L1 expression in bone marrow plasma cells as a biomarker to predict multiple myeloma prognosis: developing a nomogram-based prognostic model |
| Q58789587 | PD1 is expressed on exhausted T cells as well as virus specific memory CD8+ T cells in the bone marrow of myeloma patients |
| Q41153847 | PDL1 Expression on Plasma and Dendritic Cells in Myeloma Bone Marrow Suggests Benefit of Targeted anti PD1-PDL1 Therapy |
| Q88797022 | Prevention and treatment of relapse after stem cell transplantation with immunotherapy |
| Q35834665 | Primary myeloma interaction and growth in coculture with healthy donor hematopoietic bone marrow |
| Q36358014 | Prognostic value of PD-L1 expression in tumor infiltrating immune cells in cancers: A meta-analysis. |
| Q36322760 | Prospective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathy |
| Q103805017 | Quantitative and functional characteristics of circulating and bone marrow PD-1- and TIM-3-positive T cells in treated multiple myeloma patients |
| Q33816012 | Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myeloma |
| Q49830211 | Restoring Natural Killer Cell Immunity against Multiple Myeloma in the Era of New Drugs. |
| Q37641801 | Soluble PD-L1: A biomarker to predict progression of autologous transplantation in patients with multiple myeloma. |
| Q37390723 | T cells in multiple myeloma display features of exhaustion and senescence at the tumor site. |
| Q37517482 | The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia |
| Q57815154 | The challenges of checkpoint inhibition in the treatment of multiple myeloma |
| Q92056755 | The future of checkpoint inhibition in multiple myeloma? |
| Q92154272 | Therapeutic Monoclonal Antibodies and Antibody Products: Current Practices and Development in Multiple Myeloma |
| Q38970597 | Treatment of Relapsed/Refractory Multiple Myeloma |
| Q38730989 | Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors |
| Q59798196 | Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma |
| Q59136511 | Vγ9Vδ2 T Cells as Strategic Weapons to Improve the Potency of Immune Checkpoint Blockade and Immune Interventions in Human Myeloma |
| Q90259195 | Vγ9Vδ2 T Cells in the Bone Marrow of Myeloma Patients: A Paradigm of Microenvironment-Induced Immune Suppression |
| Q89021657 | [Advances of therapeutic strategies in hematological malignancies] |
| Q88121074 | [Advances on PD-1/PD-L1 inhibitors in multiple myeloma] |